Clinical trial · Interventional
Chemoembolization in Treating Patients With Primary Liver Cancer or Metastases to the Liver
Chemoembolization in Hepatocellular Carcinoma or Neuroendocrine Hepatic Metastases: A Phase II Multi-Center Trial
NCT00003907CI-TRIAL-00067767completedPhase 2Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Chemoembolization kills tumor cells by blocking the blood flow to the tumor and keeping chemotherapy drugs near the tumor. PURPOSE: Phase II trial to study the effectiveness of chemoembolization in treating patients who have primary liver cancer or metastases to the liver that cannot be surgically removed.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Liver Cancer | Malignant Liver Neoplasm | CURATED_EXACT | 0.92 |
| Metastatic Cancer | Malignant Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| cisplatin | Drug | Cisplatin | ALIAS |
| doxorubicin | Drug | Doxorubicin | ALIAS |
| embolization | Procedure | — | UNRESOLVED |
| mitomycin | Drug | Mitomycin | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Hepatocellular carcinoma
- description
- Chemoemulsion (doxorubicin, mitomycin and cisplatin) followed by embolization. The entire procedure will be repeated separately to each involved lobe beginning within 8 weeks of the last lobar chemoembolization.
- interventionNames
- Drug: cisplatin
- Drug: doxorubicin
- Drug: mitomycin
- Procedure: embolization
- type
- EXPERIMENTAL
- label
- Neuroendocrine hepatic metastases
- description
- Chemoemulsion (doxorubicin, mitomycin and cisplatin) followed by embolization. The entire procedure will be repeated separately to each involved lobe beginning within 8 weeks of the last lobar chemoembolization.
- interventionNames
- Drug: cisplatin
- Drug: doxorubicin
- Drug: mitomycin
- Procedure: embolization
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Biopsy-proven intrahepatic hepatocellular carcinoma or neuroendocrine tumor. * Unresectable. * Bidimensionally measurable disease by Computed Tomography (CT), Magnetic resonance imaging (MRI), or UltraSound Scanning (US) within 6 weeks of registration. * Evidence of patent portal vasculature by Doppler US, MRI, or angiography. * Serum total bilirubin \< 2.0 mg/dl and serum creatinine \< 2.0 mg/dl within 4 weeks of registration. * Absolute neutrophil count (ANC) \> 2000/µl and platelets \> 50,000/µl within 4 weeks of registration. * Expected survival of at least 3 months. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Age \>= 18 years. Exclusion Criteria: * Evidence of extrahepatic disease that is likely to be life-threatening within 3 months, such as brain or symptomatic lung metastases. * Previous intra-arterial or intra-hepatic chemotherapy or prior systemic chemotherapy within 4 weeks. * Concurrent malignancy. * Pregnant or breast-feeding women. * History of life-threatening contrast allergy.
References
Publications (0)
Data not yet available
No reference posted for this study.